1832 Asset Management
TEVA icon

1832 Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

1832 Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,718,454
Closed -$116M – 732
2025
Q4 		$116M Buy
+3,718,454
New +$91.6M 0.09% 153
2024
Q3 		– Sell
-405
Closed -$6.58K – 899
2024
Q2 		$6.58K Hold
405
– – ﹤0.01% 798
2024
Q1 		$5.71K Sell
405
-100
-20% -$1.26K ﹤0.01% 793
2023
Q4 		$5.27K Buy
505
+100
+25% +$934 ﹤0.01% 773
2023
Q3 		$4.13K Hold
405
– – ﹤0.01% 795
2023
Q2 		$3.05K Hold
405
– – ﹤0.01% 807
2023
Q1 		$3.58K Hold
405
– – ﹤0.01% 850
2022
Q4 		$3.69K Hold
405
– – ﹤0.01% 851
2022
Q3 		$3K Sell
405
-600
-60% -$5.31K ﹤0.01% 852
2022
Q2 		$8K Buy
1,005
+600
+148% +$5.23K ﹤0.01% 822
2022
Q1 		$4K Hold
405
– – ﹤0.01% 902
2021
Q4 		$3K Sell
405
-200
-33% -$1.8K ﹤0.01% 685
2021
Q3 		$6K Buy
605
+200
+49% +$1.87K ﹤0.01% 814
2021
Q2 		$4K Hold
405
– – ﹤0.01% 708
2021
Q1 		$5K Hold
405
– – ﹤0.01% 673
2020
Q4 		$4K Hold
405
– – ﹤0.01% 679
2020
Q3 		$4K Hold
405
– – ﹤0.01% 660
2020
Q2 		$5K Hold
405
– – ﹤0.01% 624
2020
Q1 		$4K Hold
405
– – ﹤0.01% 646
2019
Q4 		$4K Buy
+405
New +$3.62K ﹤0.01% 640
2019
Q2 		– Sell
-65,000
Closed -$1.02M – 753
2019
Q1 		$1.02M Buy
65,000
+64,945
+118,082% +$1.15M ﹤0.01% 384
2018
Q4 		$1K Hold
55
– – ﹤0.01% 624
2018
Q3 		$1K Hold
55
– – ﹤0.01% 638
2018
Q2 		$1K Hold
55
– – ﹤0.01% 652
2018
Q1 		$1K Sell
55
-50,000
-100% -$976K ﹤0.01% 655
2017
Q4 		$945K Sell
50,055
-25,085
-33% -$377K ﹤0.01% 440
2017
Q3 		$1.28M Buy
+75,140
New +$1.69M ﹤0.01% 405
2017
Q2 		– Sell
-43,055
Closed -$1.38M – 732
2017
Q1 		$1.38M Sell
43,055
-269,813
-86% -$9.21M ﹤0.01% 438
2016
Q4 		$36.9M Buy
312,868
+276,233
+754% +$11M 0.11% 170
2016
Q3 		$1.68M Sell
36,635
-3,166
-8% -$165K 0.01% 406
2016
Q2 		$2.01M Buy
39,801
+166
+0.4% +$8.84K 0.01% 363
2016
Q1 		$3.61M Sell
39,635
-537,074
-93% -$31.5M 0.01% 354
2015
Q4 		$38.2M Sell
576,709
-146,510
-20% -$9.05M 0.17% 128
2015
Q3 		$41M Buy
723,219
+5,040
+0.7% +$327K 0.17% 123
2015
Q2 		$42.4M Buy
718,179
+129,029
+22% +$7.96M 0.14% 149
2015
Q1 		$36.7M Sell
589,150
-275,200
-32% -$16M 0.14% 139
2014
Q4 		$49.6M Buy
864,350
+37,300
+5% +$2.08M 0.15% 132
2014
Q3 		$44.4M Buy
827,050
+77,950
+10% +$4.13M 0.15% 148
2014
Q2 		$39.3M Buy
749,100
+164,130
+28% +$8.39M 0.12% 171
2014
Q1 		$29M Buy
+584,970
New +$27M 0.1% 181

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

1832 Asset Management's TEVA Position: Q1 2026 in Review

1832 Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 3,718,454 shares — an estimated $116M sold.

1832 Asset Management first reported a position in TEVA in Q1 2014 and held it in 40 quarters. The position peaked at $116M in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • 1832 Asset Management reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • 1832 Asset Management sold 3,718,454 Teva Pharmaceuticals shares in Q1 2026, an estimated $116M.
  • 1832 Asset Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 40 quarters.
  • 1832 Asset Management's Teva Pharmaceuticals position peaked at $116M in Q4 2025.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on 1832 Asset Management's 13F filing for Q1 2026, filed 14 May 2026.